In an era where we are seeing increasing numbers of potentially curative therapies and orphan drugs for rare diseases coming to market, the industry is being faced with shifting regulatory and health technology assessment timelines. As a result, a spotlight is being turned on health technology assessment, with calls for more rapid and complex analyses, greater transparency in methods and improved efficiency.
The limits of current software are being stretched to breaking points and advanced software have the potential to revolutionize the conduct of complex health technology assessments. With a multitude of stakeholders involved at different stages of the process – from researchers to health economists, modelers to statisticians, payers to pharmaceutical companies – standardized use of advanced, efficient, reliable and capable software have never been more imperative.
For this panel discussion, we reconvened a panel of experts, with diverse field experiences, to exclusively discuss their workshop delivered at the ISPOR Europe meeting (2—6 November 2019; Copenhagen, Denmark) concerning some of the key challenges associated with utilizing current software in health technology assessment and where advanced software have the potential to steer the field.
The experts discuss:
- Key challenges associated with current software utilized in health technology assessment
- Industry requirements of software
- Advantages that advanced software may offer
- Steps we must take to implement advanced software throughout the pipeline